Michelle Doll, MD
Infectious Disease · Richmond, VANPI 1861628646
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Mylan Specialty L.p.. That places this record below the midpoint for infectious disease clinicians in VA, where the typical reported total is $169.
Across 1 payment — averaging $96.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$96
Across 1 payment — averaging $166,688 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Molnlycke Health Care AB$167K
What the payments were for
- Food & beverage$96100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 1 | $96 |
How this compares
$96 in reported general payments places this provider in the 40th percentile of 194 infectious disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 125 | $503,147 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 59 | $220,718 |
| TivicayDolutegravir Sodium | 38 | $94,024 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 21 | $70,446 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 14 | $65,900 |
| DescovyEmtricitabine/Tenofov Alafenam | 30 | $61,463 |
| PifeltroDoravirine | 20 | $35,168 |
| ErtapenemErtapenem Sodium | 12 | $8,744 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,899 |
| Rifampin | 12 | $1,457 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $1,040 |
| Azithromycin | 14 | $1,027 |
| Rosuvastatin Calcium | 36 | $527 |
| Dapsone | 16 | $493 |
| Esomeprazole Magnesium | 12 | $408 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Richmond
- Nicole VissichelliRichmond$6K
- Megan MoralesRichmond$5K
- Julie ReznicekRichmond$4K
- Benjamin BluenRichmond$701
- Christopher BettacchiMarion$243K
- Stephen WeinrothFairfax$157K
- William PetriCharlottesville$92K
- Michael IsonFalls Church$88K
- Valerie RiddleBumpass$83K
- Edward OldfieldNorfolk$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.